雷公藤多苷联合科素亚对老年IgA肾病患者的临床疗效及对TGF-β1、PAI-1及VEGF表达的影响

摘要

Objective To observe the clinical curative effect of tripterygium polyglycoside combined with cozaar in elderly patients with IgA nephropathy (IgAN) and its influence on expressions of TGF-β1,PAI-1 and VEGF.Methods Eighty elderly patients with IgA nephropathy in Jiaxing Hospital of Armed Police Zhejiang Corps from April 2011 to January 2016 were selected and randomly divided into the control group and observation group,40 cases in each group.The two groups received the routine treatment of chronic basic diseases and took oral cozaar.On this basis the observation group took tripterygium polyglycoside for continuous 12 months.Urine protein,serum creatinine (Scr),blood urea nitrogen (BUN),plasma Alb,urine TGF-β1,PAI-1 and VEGF levels before treatment and at 3,6,12 months after treatment were compared between the two groups.The occurrence situation of adverse reactions was recorded.Results The 24 h urinary protein levels at 3,6,12 months after treatment in the two groups were decreased,moreover the 24 h urine protein level at each time point in the observation group was lower than that in the control group,the difference was statistically significant (P<0.05).The levels of Scr,BUN,urine TGF-β1,PAI-1 and VEGF after treatment in the two groups were decreased compared with before treatment,while the Alb level was increased compared with before treatment,moreover the levels of Scr,BUN,urine TGF-β1,PAI-1 and VEGF in the observation group were lower than those in the control group,while the Alb level was higher than that in the control group,the difference was statistically significant (P<0.05).The observation group appeared 2 cases of leukopenia,1 case of liver dysfunction and no serious adverse reactions occurred.Conclusion Tripterygium polyglycoside combined with cozaar has a significant therapeutic effect on elderly patients with IgAN,can significantly reduce urinary protein and protect renal function,moreover its clinical use is safer.Its efficacy may be related to reducing the expression levels of TGF-β1,PAI-1 and VEGF.%目的 观察雷公藤多苷联合科素亚治疗老年IgA肾病(IgAN)的临床疗效及其对转化生长因子β1(TGF-β1)、纤溶酶原激活物抑制物-1(PAI-1)及血管内皮生长因子(VEGF)表达的影响.方法 选取2011年4月至2016年1月武警浙江总队嘉兴医院收治的老年IgA患者80例,随机分为对照组与观察组,各40例.两组患者均常规治疗慢性基础病并口服科素亚,观察组在此基础上口服雷公藤多苷,连续 12个月.比较两组治疗前及治疗3、6、12个月尿蛋白、血肌酐(Scr)、尿素氮(BUN)、血浆清蛋白(Alb)、尿TGF-β1、PAI-1及VEGF水平,记录患者不良反应发生情况.结果 治疗后3、6、12个月,两组24 h尿蛋白水平较治疗前均下降,且各时间点观察组24 h尿蛋白水平均低于对照组,差异均有统计学意义(P<0.05).治疗后,两组Scr、BUN水平及尿TGF-β1、PAI-1、VEGF水平均较治疗前降低,Alb水平较治疗前升高,且观察组Scr、BUN水平及尿TGF-β1、PAI-1、VEGF水平均低于对照组,Alb水平高于对照组,差异均有统计学意义(P<0.05).观察组出现2例白细胞减少,1例肝功能异常患者,未出现严重不良反应.结论 雷公藤多苷联合科素亚对老年IgA患者具有显著疗效,可明显降低患者尿蛋白,保护肾功能,且临床应用较安全,其可能通过降低TGF-β1、PAI-1及VEGF的表达而发挥作用.